1219 Nonclinical Safety Evaluation of Sacituzumab Govitecan, a TROP-2-directed Antibody Drug Conjugate (ADC), for Non-Muscle Invasive Bladder Cancer
Regular and Young Investigator Award Abstracts(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要